Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.73 |
| ▸ | BRD4 | O60885 | 2/20 | 0.61 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.61 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.50 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560695 | 0.94 | PLK1 (0.83) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL2295599 | 0.91 | PLK1 (0.77) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1560725 | 0.90 | PLK1 (0.71) | PLK1BRD4BRDTALKRAD52 | |
| SCHEMBL1560558 | 0.90 | PLK1 (0.87) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL26814938 | 0.89 | PLK1 (0.78) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1560401 | 0.87 | PLK1 (0.76) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1560479 | 0.87 | PLK1 (0.75) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL26815286 | 0.87 | PLK1 (0.75) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1559311 | 0.86 | PLK1 (0.71) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1559376 | 0.86 | PLK1 (0.74) | PLK1BRD4BRDTPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | claimed |
| US-8003785-B2 | Halo-substituted pyrimidodiazepines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003785-B2 | Halo-substituted pyrimidodiazepines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2303889-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | PLK1 1/4885BRD4 58/4885BRDT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.